Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05973487 · View on ClinicalTrials.gov ↗

Study Summary

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.

Interventions

  • BIOLOGICAL TSC-204-A0201
  • BIOLOGICAL TSC-204-C0702
  • BIOLOGICAL TSC-200-A0201
  • BIOLOGICAL TSC-204-A0201 + TSC-204-C0702
  • BIOLOGICAL TSC-204-A0201 + TSC-200-A0201

Study Locations (20)

Florida

  • Memorial Healthcare System — Hollywood
  • University of Miami, Sylvester Comprehensive Cancer Center — Miami
  • Orlando Health — Orlando
  • University of South Florida — Tampa

Ohio

  • Oncology Hematology Care — Cincinnati
  • The Cleveland Clinic — Cleveland

Pennsylvania

  • Allegheny Hospitals Network — Pittsburgh
  • University of Pittsburgh Medical Center — Pittsburgh

Arizona

  • HonorHealth Research and Innovation Institute — Scottsdale

California

  • University of California San Diego — San Diego

Connecticut

  • Yale Cancer Center — New Haven

Illinois

  • University of Chicago — Chicago

Kentucky

  • Norton Cancer Institute — Louisville

Trial Details

FieldValue
Enrollment Target 840 participants
Start Date 2024-05-06
Est. Completion 2026-12-30
Phase Phase 1

Sponsor

TScan Therapeutics

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05973487

The ClinicalTrials.gov registry entry for NCT05973487 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TScan Therapeutics, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions — of which TSC-204-A0201 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05973487 reports 20 study locations spanning 15 distinct geographic areas — top geographies include Florida, Ohio, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05973487 about?

NCT05973487 is a clinical study titled "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors". TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a...

What is the current status of trial NCT05973487?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 840 participants. The study started on 2024-05-06. Estimated completion is 2026-12-30.

What conditions does trial NCT05973487 study?

This clinical trial studies the following conditions: Ovarian Cancer, Melanoma, Head and Neck Cancer, Cervical Cancer, HPV-Related Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05973487?

The interventions under investigation include: TSC-204-A0201 (BIOLOGICAL), TSC-204-C0702 (BIOLOGICAL), TSC-200-A0201 (BIOLOGICAL), TSC-204-A0201 + TSC-204-C0702 (BIOLOGICAL), TSC-204-A0201 + TSC-200-A0201 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05973487?

This trial is sponsored by TScan Therapeutics, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05973487 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial